Free Trial

Enlivex Therapeutics (ENLV) Stock Price, News & Analysis

+0.03 (+2.21%)
(As of 05/24/2024 03:59 PM ET)
Today's Range
50-Day Range
52-Week Range
25,500 shs
Average Volume
144,531 shs
Market Capitalization
$26.04 million
P/E Ratio
Dividend Yield
Price Target

Enlivex Therapeutics MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
400.0% Upside
$7.00 Price Target
Short Interest
1.42% of Shares Sold Short
Dividend Strength
News Sentiment
0.99mentions of Enlivex Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($0.86) to ($0.55) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.45 out of 5 stars

Medical Sector

320th out of 921 stocks

Pharmaceutical Preparations Industry

147th out of 426 stocks

ENLV stock logo

About Enlivex Therapeutics Stock (NASDAQ:ENLV)

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

ENLV Stock Price History

ENLV Stock News Headlines

ENLV Apr 2024 7.500 call
Enlivex Therapeutics Ltd.
ENLV May 2024 5.000 put
Enlivex Therapeutics Ltd ENLV
See More Headlines
Receive ENLV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enlivex Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
1 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$1.62 per share


Free Float
Market Cap
$26.04 million
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Shai Novik M.B.A. (Age 58)
    Executive Chairman
    Comp: $528k
  • Dr. Oren Hershkovitz Ph.D. (Age 47)
    Chief Executive Officer
    Comp: $273.6k
  • Prof. Dror Mevorach M.D. (Age 68)
    Founder and Chief Scientific & Medical Officer
    Comp: $180k
  • Ms. Shachar Shlosberger CPA (Age 47)
    Chief Financial Officer
    Comp: $126k
  • Mr. Veronique Amor-Baroukh
    Senior Director of Operations
  • Ms. Sigal Arad
    Director of HR

ENLV Stock Analysis - Frequently Asked Questions

Should I buy or sell Enlivex Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enlivex Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ENLV shares.
View ENLV analyst ratings
or view top-rated stocks.

What is Enlivex Therapeutics' stock price target for 2024?

1 Wall Street analysts have issued 12 month price objectives for Enlivex Therapeutics' shares. Their ENLV share price targets range from $7.00 to $7.00. On average, they expect the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 400.0% from the stock's current price.
View analysts price targets for ENLV
or view top-rated stocks among Wall Street analysts.

How have ENLV shares performed in 2024?

Enlivex Therapeutics' stock was trading at $2.70 at the beginning of the year. Since then, ENLV shares have decreased by 48.1% and is now trading at $1.40.
View the best growth stocks for 2024 here

When is Enlivex Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, June 21st 2024.
View our ENLV earnings forecast

How were Enlivex Therapeutics' earnings last quarter?

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) posted its earnings results on Friday, March, 29th. The company reported ($0.48) earnings per share (EPS) for the quarter.

What other stocks do shareholders of Enlivex Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enlivex Therapeutics investors own include VBI Vaccines (VBIV), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Occidental Petroleum (OXY), Pfizer (PFE), Amarin (AMRN), Fulcrum Therapeutics (FULC), Soleno Therapeutics (SLNO), Sorrento Therapeutics (SRNE) and Vaxart (VXRT).

How do I buy shares of Enlivex Therapeutics?

Shares of ENLV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ENLV) was last updated on 5/27/2024 by Staff

From Our Partners